Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

205.34 +1.03 (+0.50%)

Streaming Delayed Price Updated: 2:34 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment ↗

Today 13:42 EST

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.

Via Benzinga

The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026

Today 10:22 EST

As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...

Via MarketMinute

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

January 05, 2026

Via MarketBeat

Topics Artificial Intelligence Death

3 High-Yielding Dividend Kings to Buy in January for Safe Passive Income in 2026 and Beyond ↗

January 05, 2026

These companies pay high-yielding and steadily rising dividends.

Via The Motley Fool

2 Healthcare Stocks to Buy in a Bear Market ↗

January 03, 2026

They can help you weather the storm.

Via The Motley Fool

Topics Economy

Dividend Growers: 3 Stocks That Could Be Worth $1 Million in 36 Years. ↗

January 03, 2026

These dividends should continue growing.

Via The Motley Fool

Santa’s Empty Sleigh: Why the 2025 Rally Failure Signals a Rough Q1 for Wall Street

January 02, 2026

The highly anticipated "Santa Claus Rally" of 2025 has officially failed to materialize, leaving investors with a lump of coal as they ring in the new year. While the broader market enjoyed a year of...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

Topics Economy Intellectual Property World Trade

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

January 02, 2026

From Johnson & Johnson

Via Business Wire

Johnson & Johnson Near Year High ↗

January 01, 2026

Johnson & Johnson is nearing its 52-week high, driven by strong momentum and positive news, raising expectations for its upcoming earnings report amidst heightened sensitivity to market trends.

Via Talk Markets

Want Decades of Passive Income? 2 Stocks to Buy Right Now ↗

January 01, 2026

These income stocks could be great buys to add to your portfolio.

Via The Motley Fool

Topics Intellectual Property

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

S&P 500 Eyes 7,000 Milestone: Technical Breakout Sets the Stage for a High-Stakes 2026

December 31, 2025

As the final closing bell of 2025 rings on Wall Street, the S&P 500 (SPX) stands on the precipice of history. After a year defined by a "triple-tailwind" of aggressive Federal Reserve easing, a...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Palantir Shares Retreat to $180.80 as Hawkish Fed Minutes and Institutional Rebalancing Cool Year-End Rally

December 30, 2025

Palantir Technologies (NYSE: PLTR) saw its shares slide in after-hours trading on Tuesday, December 30, 2025, as a combination of hawkish signals from the Federal Reserve and aggressive year-end...

Via MarketMinute

Topics Artificial Intelligence Economy

The Trillion-Dollar Shuffle: How Year-End Institutional Rebalancing is Fueling Late-December Volatility

December 30, 2025

As the final trading days of 2025 unfold, the financial markets are witnessing a phenomenon that analysts have dubbed the "Great Rebalancing." While the S&P 500 is poised to finish the year with...

Via MarketMinute

Topics Artificial Intelligence Bonds ETFs

The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal

December 30, 2025

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Hunterbrook Capital Bets Big on Achieve Life Sciences: Why a 'Toxic Tree' Could Disrupt the Multi-Billion Dollar Smoking Cessation Market

December 30, 2025

In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV)...

Via MarketMinute

Topics Product Recall

The S&P 500 Seesaw: Analyzing IVV’s Year-End Turbulence After a Record-Breaking 2025

December 30, 2025

The financial markets are closing out 2025 in a state of high-octane paradox. The iShares Core S&P 500 ETF (NYSE Arca: IVV), the massive exchange-traded fund that serves as a cornerstone for millions...

Via MarketMinute

Topics ETFs Economy Retirement

Wall Street Stumbles at the Finish Line: S&P 500 and Nasdaq Fight to Break 3-Day Slide Amid Year-End Rebalancing

December 30, 2025

As the 2025 trading calendar winds down to its final hours, the festive atmosphere on Wall Street has been replaced by a clinical, high-stakes battle for technical support. On this Tuesday, December...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year

December 30, 2025

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever ↗

December 30, 2025

Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.

Via The Motley Fool

Topics Economy Intellectual Property

Could These 3 "Recession-Proof" Dividend Stocks Surge 100% by 2031? ↗

December 29, 2025

All three are buys, but for different reasons.

Via The Motley Fool

Topics Artificial Intelligence Economy Intellectual Property

The Santa Claus Stumble: Markets Pivot from Record Highs to Year-End Consolidation

December 29, 2025

As the final trading days of 2025 unfold, the festive exuberance that propelled Wall Street to the brink of historic milestones is beginning to cool. After a blistering mid-December surge that saw the...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The Price of Prosperity: Navigating the S&P 500’s Historic Valuation Peak as 2026 Dawns

December 29, 2025

As the final trading days of 2025 draw to a close, the financial world finds itself standing on a high-altitude plateau that few predicted and many fear. The S&P 500 (INDEXSP: .INX) enters 2026 trading...

Via MarketMinute

Topics Artificial Intelligence Bonds Earnings

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

December 29, 2025

From Johnson & Johnson

Via Business Wire

Blue-Chip Bull Run: Dow Jones Eyes 50,000 Milestone Amidst 2026 Technical Pivot

December 26, 2025

As the final bells of 2025 ring across the floor of the New York Stock Exchange, the Dow Jones Industrial Average (DJI) stands at a historic crossroads. After a year defined by a resilient "soft...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot

December 26, 2025

As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Johnson & Johnson Terminates Experimental Eczema Drug Study After It Fails To Show Benefit ↗

December 26, 2025

The company said that the drug did not achieve the “high-bar””efficacy targets in a planned interim analysis.

Via Stocktwits

Johnson & Johnson Halts Atopic Dermatitis Study After Interim Analysis Miss ↗

December 26, 2025

Johnson & Johnson's Phase 2b study for atopic dermatitis did not meet high-bar efficacy and was terminated early.

Via Benzinga

Baxter International (BAX) in 2025: A Deep Dive into the Transformation of a MedTech Giant

December 26, 2025

As of December 26, 2025, Baxter International Inc. (NYSE: BAX) stands at a pivotal crossroads in its nearly century-long history. Long considered a defensive "blue-chip" staple of the healthcare...

Via PredictStreet

Topics Economy Emissions Product Recall

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.